Analytical Data
-
Gene name
GZMA
- Application
-
Alternative Names
GZMA；CTLA3；HFSP；Granzyme A
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P12544
-
Expression Region
29-262aa
-
AA Sequence
II GGNEVTPHSR PYMVLLSLDR KTICAGALIA KDWVLTAAHC NLNKRSQVIL GAHSITREEP TKQIMLVKKE FPYPCYDPAT REGDLKLLQL MEKAKINKYV TILHLPKKGD DVKPGTMCQV AGWGRTHNSA SWSDTLREVN ITIIDRKVCN DRNHYNFNPV IGMNMVCAGS LRGGRDSCNG DSGSPLLCEG VFRGVTSFGL ENKCGDPRGP GVYILLSKKH LNWIIMTIKG AV
-
Molecular Weight
28.9 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
GZMA, or Granzyme A, is a serine protease that plays a crucial role in the immune response, particularly in the apoptosis of target cells during cytotoxic T lymphocyte and natural killer cell-mediated cytotoxicity. The research surrounding recombinant GZMA has gained traction due to its potential applications in immunotherapy and cancer treatment. GZMA is secreted by cytotoxic lymphocytes and enters target cells through perforin-mediated endocytosis, leading to the activation of apoptotic pathways. Understanding the structure and function of GZMA is vital for elucidating its mechanism of action and enhancing its therapeutic utility. Recombinant GZMA can be utilized to study its interactions with various substrates and to develop novel therapeutic agents that can modulate immune responses, particularly in cancer and viral infections. Advances in recombinant DNA technology facilitate the production of high-purity GZMA, allowing for more precise investigations into its enzymatic activity, specificity, and potential in targeted therapies. Additionally, as research continues to uncover the complexities of immune evasion by tumors, GZMA holds promise in overcoming these challenges by inducing apoptosis in malignant cells. Overall, the exploration of recombinant GZMA not only enhances our understanding of immune mechanisms but also paves the way for innovative strategies in treating diseases characterized by dysregulated cell survival.
